Chris Bruno spoke at IP Watchdog’s Life Sciences Masters 2024 on the panel, “Obviousness and Life Sciences: Trends & Strategies for Success.” His panel discussed obviousness generally, and specifically the interplay between 35 USC 103 and 35 USC 112, the use of clinical trials as the foundation for an obviousness rejection, and the use of secondary considerations to prove, or disprove, obviousness.

The program explored the law, politics, and business of life sciences. To learn more, visit the event website.